279 related articles for article (PubMed ID: 8801864)
1. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
3. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
5. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
6. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
[TBL] [Abstract][Full Text] [Related]
7. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Yu L; Qiu S; Genest J
Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
[TBL] [Abstract][Full Text] [Related]
8. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
9. Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.
Illingworth DR; Bacon S
Arteriosclerosis; 1989; 9(1 Suppl):I121-34. PubMed ID: 2492189
[TBL] [Abstract][Full Text] [Related]
10. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
11. Treating hypercholesterolaemia with HMG CoA reductase inhibitors: a direct comparison of simvastatin and pravastatin.
Lintott CJ; Scott RS; Sutherland WH; Bremer J
Aust N Z J Med; 1993 Aug; 23(4):381-6. PubMed ID: 8240151
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of tolerance, efficacy and safety of 3-year simvastatin use in the treatment of primary hypercholesterolemia].
Darioli R; Bovet P; Brunner HR; Bercher L
Schweiz Med Wochenschr; 1990 Jan; 120(4):85-91. PubMed ID: 2305221
[TBL] [Abstract][Full Text] [Related]
13. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
[TBL] [Abstract][Full Text] [Related]
14. Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Tilly-Kiesi M; Tikkanen MJ
J Intern Med; 1991 May; 229(5):427-34. PubMed ID: 2040869
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Feillet C; Farnier M; Monnier LH; Percheron C; Colette C; Descomps B; Crastes De Paulet A
Atherosclerosis; 1995 Dec; 118(2):251-8. PubMed ID: 8770319
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
McPherson R; Bedard J; Connelly P; Curnew G; Davignon J; Echenberg D; Lavin P; Leiter L; Lenis J; McQueen M
Clin Ther; 1992; 14(2):276-91. PubMed ID: 1611649
[TBL] [Abstract][Full Text] [Related]
19. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors.
Bargossi AM; Grossi G; Fiorella PL; Gaddi A; Di Giulio R; Battino M
Mol Aspects Med; 1994; 15 Suppl():s187-93. PubMed ID: 7752830
[TBL] [Abstract][Full Text] [Related]
20. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
Heath KE; Gudnason V; Humphries SE; Seed M
Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
